Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
Yang
Wei-Shun
WS
Chu
Pei-Lun
PL
Liu
Chen-Hua
CH
Chung
Guei-Bin
GB
Wu
Kwan-Dun
KD
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002231:Carbimazole / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011782:Quadriplegia / Q000139:chemically induced* / Q000188:drug therapy; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000139:chemically induced* / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D013956:Antithyroid Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D002231:Carbimazole; D011433:Propranolol; C100416:peginterferon alfa-2a